Thermo Fisher Scientific is slated to buy electron microscope maker FEI Company for $4.2 billion, the firms announced last week (May 27). According to The New York Times, the aquisition is expected to close by early 2017.
“Fundamentally, this transaction bolsters our already strong position in the marketplace and allows us to play an increasing role in enabling our customers to accelerate breakthrough discoveries, increase productivity, and provide solutions to global challenges,” FEI’s Don Kania, president and chief executive officer, said in a statement.
“In life sciences, there is growing adoption of electron microscopy to study the structure of proteins,” Marc Casper, Thermo Fisher chief executive officer, said in a statement. “The technologies we gain with FEI will complement our mass spectrometry leadership, putting Thermo Fisher in the best position to capitalize on this important trend.”
Just two months ago, Casper’s company closed another large acquisition deal: Thermo Fisher bought Affymetrix for $1.3 billion.
By Tracy Vence
Source: The Scientist
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.